A-FLUX Reducer for Microvascular Angina

(SERRA-I US Trial)

This trial tests a device called the A-FLUX Reducer System to assist individuals with angina or similar symptoms due to coronary microvascular dysfunction, a condition affecting small heart blood vessels. The study aims to evaluate the safety and effectiveness of this treatment in relieving symptoms. It suits individuals who have experienced ongoing angina symptoms for over 30 days despite medication. Participants must be willing to follow study procedures and have a heart function score above a specified level. This trial offers a chance to try a new treatment that might better manage symptoms. As an unphased trial, it provides an opportunity to explore innovative treatment options that could improve quality of life.

The trial does not specify if you need to stop your current medications. However, it mentions that participants should be on optimal medical therapy, which includes at least two anti-anginal medications or the maximum tolerated therapy if fewer than two. It's best to discuss your specific medications with the trial team.

Research has shown that the A-FLUX Reducer System is generally safe for people. In a study where patients used it for the first time, the procedure proved safe and had no complications, indicating patients tolerated the treatment well during and immediately after. Another study, which applied the device in special cases, also found it safe, with patients demonstrating lasting improvements. Although the device remains in early testing, these results suggest it is safe so far.¹²³⁴⁵

The A-FLUX Reducer System is unique because it offers a novel approach to treating microvascular angina, which is often resistant to traditional medications like beta-blockers and calcium channel blockers. Unlike these standard treatments, which primarily focus on reducing heart workload and managing symptoms, the A-FLUX Reducer System is designed to enhance blood flow in the small vessels of the heart by physically modifying the structure of the coronary sinus. This innovative method could potentially improve symptoms and quality of life for patients with microvascular angina who do not respond to existing therapies. Researchers are excited because this approach targets the root cause of microvascular dysfunction, offering hope for more effective relief.

Research shows that the A-FLUX Reducer System, which trial participants will receive, may alleviate chest pain symptoms. Studies have found that patients experience improved well-being and quality of life. Specifically, patients reported less chest pain and discomfort, as measured by specific questionnaires. The device lowers pressure in a large vein in the heart, potentially enhancing blood flow in smaller vessels. Although further research is necessary, these early results offer promise for individuals with chest pain due to small blood vessel issues.¹²³⁴⁶